miR-181a在卵巢癌细胞中对顺铂的耐药作用

目的 探讨miR-181a在卵巢癌化疗抵抗方面的影响及其机制.方法 qRT-PCR检测卵巢癌细胞A2780及 A2780/DDP 中 miR-181a 的表达;对 A2780及 A2780/DDP 细胞分别进行 miR-181a mimics 和 inhibitors的转染,并利用qRT-PCR技术验证;MTT法检测转...

Studies on Cisplatin Resistance of miR-181a in Ovarian Cancer Cells

  Objective  To investigate the effect of miR-181a on chemotherapy resistance of ovarian cancer and its regulatory mechanism.   Methods  Real-time PCR was used to detect the expression of miR-181a in A2780 and cisplatin resistant cell lines （A2780/DDP）, and siltation/overexpression changed the expression of miR-181a in A2780 and A2780/DDP cells. MTT method was used to determine the sensitivity of cells to cisplatin before and after the transfection. Three MicroRNA target gene databases, TargetScan, miRDB and miRwalk, were used to predict the downstream targets of miR-181a, and the changes in protein expression of target genes were analyzed by Western blot.   Results  Compared with A2780 cells, the expression of miR-181a in A2780/DDP cells was significantly decreased （P < 0.05）. After the transfection of A2780 cells with miR-181a inhibitor （interfering with Mir-181A expression）, the sensitivity of A2780 cells to cisplatin decreased （P < 0.05）, and after the transfection of A2780/DDP cells with miR-181a mimic （overexpressing miR-181a）, The sensitivity of cells to cisplatin was increased （P < 0.05）. It was predicted that PRKCD could be used as the downstream target gene of miR-181a by TargetScan, miRDB and miRwalk databases, and down-regulation of miR-181a expression could significantly enhance PRKCD protein expression （P < 0.05）. On the contrary, up-regulation of miR-181a significantly inhibited PRKCD protein expression （P < 0.05）.   Conclusion  miR-181a may inhibit cisplatin resistance of ovarian cancer cell A2780 by regulating PRKCD.